Aerovate Therapeutics AVTE

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    +$0.03 (+1.20%)Past DayToday's Volume:
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Business overview of Aerovate Therapeutics (AVTE)
    Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. The initial focus of the company is on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension.

    Key Insights

    Critical company metrics and information

    • Latest Closing Price

      $2.53

    • Market Cap

      $73.33 Million

    • Price-Earnings Ratio

      -0.85

    • Total Outstanding Shares

      28.88 Million Shares

    • Total Employees

      51

    • Dividend

      No dividend

    • IPO Date

      June 30, 2021

    • SIC Description

      Pharmaceutical Preparations

    • Primary Exchange

      NASDAQ

    • Type

      Common Stock

    • Headquarters

      930 winter street, Waltham, MA, 02451

    • Homepage

      https://www.aerovatetx.com

    Historical Stock Splits

    Execution DateSplit Amount
    No Historical Stock Splits

    Cash Flow Statement

    October 1, 2023 to September 30, 2024
    MetricValue
    Net Cash Flow From Operating Activities$-74.95 Million
    Net Cash Flow From Financing Activities$25.34 Million
    Net Cash Flow From Financing Activities, Continuing$25.34 Million
    Net Cash Flow$-1.06 Million
    Net Cash Flow From Investing Activities, Continuing$48.55 Million
    Net Cash Flow, Continuing$-1.06 Million

    Income Statement

    October 1, 2023 to September 30, 2024
    MetricValue
    Other Operating Expenses$20.79 Million
    Net Income/Loss$-84.61 Million
    Research and Development$69.47 Million
    Operating Expenses$90.26 Million
    Revenues$0
    Income/Loss From Continuing Operations Before Tax$-84.56 Million

    Comprehensive Income

    October 1, 2023 to September 30, 2024
    MetricValue
    Other Comprehensive Income/Loss$447,000
    Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
    Comprehensive Income/Loss Attributable To Parent$-84.16 Million
    Comprehensive Income/Loss$-84.16 Million

    Balance Sheet

    October 1, 2023 to September 30, 2024
    MetricValue
    Cash$88.70 Million
    Prepaid Expenses$993,000
    Liabilities And Equity$90.96 Million
    Fixed Assets$14,000
    Other Current Assets$912,000
    Equity Attributable To Noncontrolling Interest$0

    Historical Dividends

    Announcement DatePayment DateRecord DateAmountFrequency
    No historical dividends

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about AVTE from trusted financial sources
      Boost your savings and earn 4.15% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
      All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

      â“’ 2025 Financhle. All Rights Reserved.